April 14, 2020
The broad spectrum of clinical manifestations seen in systemic lupus erythematosus (SLE) makes it challenging to characterize the disease meaningfully. Particularly problematic for researchers and physicians alike is the apparent classification of differences between acute episodes and chronic disease damage.
To that end, the SLE disease activity index (SLEDAI-2K) functions to standardize the assessment of disease severity by clinicians globally. This tool consists of 24 weighted variables (eight laboratory and 16 clinical) of nine organ systems for disease activity1.